Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 174,100 shares, a drop of 80.8% from the January 15th total of 909,000 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 4,260,000 shares, the days-to-cover ratio is presently 0.0 days.

Windtree Therapeutics Price Performance

WINT stock opened at $0.17 on Thursday. The company has a market cap of $1.88 million, a price-to-earnings ratio of -0.01 and a beta of 0.53. The company has a fifty day moving average price of $0.26 and a 200 day moving average price of $2.61. Windtree Therapeutics has a 12 month low of $0.10 and a 12 month high of $14.75.

Windtree Therapeutics (NASDAQ:WINT) last announced its earnings results on Tuesday, November 26th. The company reported ($4.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.27) by ($1.96). As a group, analysts anticipate that Windtree Therapeutics will post -5.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating and set a $7.00 price target on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.